![New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition with XARELTO Plus Aspirin in Patients with Coronary Artery Disease, Peripheral Artery Disease | DAIC New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition with XARELTO Plus Aspirin in Patients with Coronary Artery Disease, Peripheral Artery Disease | DAIC](https://www.dicardiology.com/sites/default/files/styles/content_feed_large_new/public/Xarelto%20Trial.png?itok=OUkfC9zb)
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition with XARELTO Plus Aspirin in Patients with Coronary Artery Disease, Peripheral Artery Disease | DAIC
![Rivaroxaban program for acute venous thromboembolism upon ED discharge, with focus on utility of commercially available dose pack - ScienceDirect Rivaroxaban program for acute venous thromboembolism upon ED discharge, with focus on utility of commercially available dose pack - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0735675717306484-gr2.jpg)
Rivaroxaban program for acute venous thromboembolism upon ED discharge, with focus on utility of commercially available dose pack - ScienceDirect
![Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial | Scientific Reports Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-56887-w/MediaObjects/41598_2019_56887_Fig1_HTML.png)